GTBP · GT Biopharma Inc
United States · RS rating 90 · As of 2026-10-14
| Price | 6.21 USD |
|---|---|
| 1-day change | -4.5% |
| RS rating (overall / 1M / 3M / 12M) | 90 / 6 / 99 / 99 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 40 / 53 / 50 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -9.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +46.6% |
| Market cap (USD) | $11.3M |